HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE (“Company”) declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49 (0) 151 1940 5058 (m), volker.braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
Ottawa, Ontario--(Newsfile Corp. - May 29, 2025) - Angelita Graham is taking on the role…
MADISON, Wis., May 29, 2025 /PRNewswire/ -- Nordic® today announced it has joined the ServiceNow Partner…
Scheduling Now Open; Appointments Begin June 2, 2025 CINCINNATI, May 29, 2025 /PRNewswire/ -- HerMD,…
DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- 360Quadrants has released its latest Gold Nanoparticles Startups/SMEs…
Allegheny Health Network reports 10% revenue growth, $8 million operating income, more-than-doubles EBITDA year-over-yearHighmark Health…
DELRAY BEACH, Fla., May 29, 2025 /PRNewswire/ -- The global Electronic Lab Notebook Market, valued at…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
